Advertisement
Australia markets closed
  • ALL ORDS

    8,070.10
    -9.10 (-0.11%)
     
  • ASX 200

    7,822.30
    -9.50 (-0.12%)
     
  • AUD/USD

    0.6744
    +0.0016 (+0.24%)
     
  • OIL

    83.72
    -0.16 (-0.19%)
     
  • GOLD

    2,394.70
    +25.30 (+1.07%)
     
  • Bitcoin AUD

    84,029.40
    -2,209.48 (-2.56%)
     
  • CMC Crypto 200

    1,178.62
    -30.08 (-2.49%)
     
  • AUD/EUR

    0.6226
    +0.0006 (+0.10%)
     
  • AUD/NZD

    1.0983
    -0.0009 (-0.09%)
     
  • NZX 50

    11,794.81
    +48.15 (+0.41%)
     
  • NASDAQ

    20,397.98
    +211.35 (+1.05%)
     
  • FTSE

    8,203.93
    -37.33 (-0.45%)
     
  • Dow Jones

    39,316.06
    +8.06 (+0.02%)
     
  • DAX

    18,475.45
    +24.97 (+0.14%)
     
  • Hang Seng

    17,799.61
    -228.67 (-1.27%)
     
  • NIKKEI 225

    40,912.37
    -1.28 (-0.00%)
     

Altimmune to Participate at Leerink Partners Therapeutics Forum

Altimmune, Inc
Altimmune, Inc

GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will be hosting one-on-one meetings with institutional investors at the Leerink Partners Therapeutics Forum: I&I and Metabolism, being held on July 9 and 10, 2024 in Boston, MA. The event will feature analyst-hosted panel discussions with leading physicians in a range of autoimmune and metabolic indications, as well as meetings between participating companies and investors.

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.

ADVERTISEMENT

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Company Contact:
Vipin Garg
President and Chief Executive Officer
Phone: 240-654-1450
ir@altimmune.com

Investor Contacts:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com

Julia Weilman
Burns McClellan
Phone: 646-732-4443
jweilman@burnsmc.com

Media Contact:
Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com